Omega-3 Fatty Acids to Combat Sarcopenia

Mayo Clinic24 enrolled

Overview

The purpose of this study is to determine how omega-3 fatty acids influence muscle protein metabolism and mitochondrial physiology in the context of human aging.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Sarcopenia

Interventions

Omega-3 fatty acidsDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 85 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Age 18-35 or 65-85 years Exclusion Criteria: 1. Current use of omega-3 nutritional supplements 2. Fasting plasma glucose ≥126 mg/dL 3. Active coronary artery disease 4. Participation in structured exercise (\>3 times per week for 30 minutes or longer) 5. Smoking 6. Medications known to affect muscle metabolism (e.g., beta blockers, corticosteroids, tricyclic-antidepressants, benzodiazepines, opiates, barbiturates, anticoagulants) 7. Renal failure (serum creatinine \> 1.5mg/dl) 8. Chronic active liver disease (Bilirubin \> 17mmol/L, AST\>144IU/L, or ALT\>165IU/L) 9. Anti-coagulant therapy (warfarin/heparin) 10. INR \>3 11. Use of systemic glucocorticoids 12. Chronic use of NSAIDS or aspirin 13. Pregnancy or breastfeeding 14. Alcohol consumption greater than 2 glasses/day 15. Hypothyroidism 16. Fish or shellfish allergy

Locations (1)

Mayo Clinic

Rochester, Minnesota, United States

Outcomes

Primary Outcomes

Change in Muscle protein synthesis

Skeletal muscle protein synthesis will be measured from the rate of incorporation of infused amino acids measured by mass spectrometry.

Time frame: Baseline and following 4 months intervention

Change in Muscle mitochondrial function

Mitochondrial function will be measured in isolated mitochondria by high-resolution respirometry.

Time frame: Baseline and following 4 months intervention

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.